Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 6,992 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Carcinoma Clear all
Completed Phase 2 Interventional Results available

Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction

NCT02525718
View directory record Official record
Conditions
Breast Cancer
Interventions
Saline, 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 16, 2026, 9:53 AM EDT
Completed Phase 1 Interventional

Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer

NCT00582920
View directory record Official record
Conditions
Osseous Lesions From Metastatic Breast Cancer
Interventions
Zometa™
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 16, 2026, 9:53 AM EDT
Not yet recruiting Not applicable Interventional

Molecular Breast Imaging (MBI)-Guided Biopsy

NCT07114679
View directory record Official record
Conditions
Breast Cancer Detection, Breast Neoplasm, Molecular Imaging, Biopsy, Dense Breasts
Interventions
Molecular Breast Imaging, MBI-guided biopsy
Device
Lead sponsor
Smart Breast Corp.
Industry
Eligibility
21 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 16, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 16, 2026, 9:53 AM EDT
Recruiting Phase 4 Interventional Results available

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

NCT03096418
View directory record Official record
Conditions
Breast Neoplasm Female
Interventions
Paclitaxel
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 16, 2026, 9:53 AM EDT
Completed No phase listed Observational

The Effect of Dexmedetomidine of the Immune System

NCT01692210
View directory record Official record
Conditions
Breast Cancer
Interventions
Dexmedetomidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 16, 2026, 9:53 AM EDT
Completed Not applicable Interventional

HIIT Following Breast Cancer Chemotherapy

NCT05913713
View directory record Official record
Conditions
Breast Cancer
Interventions
12-week Intervention Period, 12-week Observation Period
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 16, 2026, 9:53 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients

NCT01473680
View directory record Official record
Conditions
Breast Cancer
Interventions
EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 61 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 16, 2026, 9:53 AM EDT
Active, not recruiting Not applicable Interventional

Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout®

NCT05825482
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm 1 Partial mastectomy with Savi Scout® localization and shave margins., Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 16, 2026, 9:53 AM EDT
Recruiting Phase 1 Interventional

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT07229313
View directory record Official record
Conditions
Advance Solid Tumors
Interventions
KIVU-107
Drug
Lead sponsor
Kivu Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Santa Monica, California • New Have, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 16, 2026, 9:53 AM EDT
Completed Not applicable Interventional

Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy

NCT03964896
View directory record Official record
Conditions
Breast Carcinoma, Head and Neck Carcinoma, Sarcoma
Interventions
Survey, Survey Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 16, 2026, 9:53 AM EDT
Terminated Early Phase 1 Interventional

Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT

NCT00725946
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
Interventions
Iodine-124, PET/CT with Iodine-124
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 16, 2026, 9:53 AM EDT
Completed Phase 4 Interventional

Interpersonal Therapy for Depression in Breast Cancer

NCT01191580
View directory record Official record
Conditions
Major Depression
Interventions
Interpersonal Psychotherapy, Problem-Solving Therapy, Brief Supportive Psychotherapy
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 16, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Taxotere

NCT00206505
View directory record Official record
Conditions
Breast Cancer
Interventions
Taxotere
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 16, 2026, 9:53 AM EDT
Available No phase listed Expanded access

BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast

NCT04091295
View directory record Official record
Conditions
Pancreatic Cancer, Osteosarcoma, MPNST (Malignant Peripheral Nerve Sheath Tumor), Chondrosarcoma, Soft Tissue Sarcoma, Chordoma, Sarcoma, Carcinoma of Breast, Single Patient IND for Glioblastoma, Ovarian Carcinoma, Non-small Cell Lung Cancer , Prostate Cancer
Interventions
DNG64-CAR-V
Drug
Lead sponsor
Aveni Foundation
Other
Eligibility
12 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 16, 2026, 9:53 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

NCT01194869
View directory record Official record
Conditions
Breast Cancer
Interventions
Sorafenib, Cisplatin, Paclitaxel
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 16, 2026, 9:53 AM EDT
Recruiting Phase 1 Interventional

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069
View directory record Official record
Conditions
Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions
LY4052031, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 9:53 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

NCT03428802
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 16, 2026, 9:53 AM EDT
Recruiting Phase 2 Interventional

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy

NCT06185205
View directory record Official record
Conditions
Breast Cancer
Interventions
Accelerated partial breast irradiation
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
45 Years to 79 Years · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 16, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

NCT06125522
View directory record Official record
Conditions
Breast Cancer
Interventions
vepdegestrant, Samuraciclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer

NCT00003351
View directory record Official record
Conditions
Breast Cancer
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
21
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 16, 2026, 9:53 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Sexual Health Empowerment for Women's Health

NCT03984695
View directory record Official record
Conditions
Cervical Cancer, Breast Cancer, Contraceptive Usage, Sexually Transmitted Diseases
Interventions
SHE-WOMEN
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 16, 2026, 9:53 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

NCT00436254
View directory record Official record
Conditions
HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions
pNGVL3-hICD vaccine, sargramostim, flow cytometry, immunologic technique, immunoenzyme technique, protein expression analysis, biopsy
Biological · Other · Genetic + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 16, 2026, 9:53 AM EDT
Completed Not applicable Interventional

Changes in Cancer-related Cytokines After Participation in a Physical Activity Behavior Change Intervention (CICK Study)

NCT00640666
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Behavior Change
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 16, 2026, 9:53 AM EDT